Cellectis (CLLS) Share-based Compensation (2015 - 2026)
Cellectis (CLLS) posted quarterly Share-based Compensation of $1.7 million for Q1 2026, up 70.39% year-over-year from $976000.0 in Q1 2025, and down 26.09% quarter-over-quarter from $2.2 million in Q4 2025.
Cellectis (CLLS) Share-based Compensation (2015 - 2026) Analysis & Trends
Cellectis' Share-based Compensation history runs 12 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 70.39% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $6.8 million (up 108.75% YoY), while the FY2025 annual figure was $6.1 million, up 92.93% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.7 million, down from $2.2 million in the prior quarter.
- The five-year high for Share-based Compensation was $4.6 million in Q4 2023, with the low at -$2.7 million in Q3 2023.
- The 5-year median for Share-based Compensation is $1.3 million (2022), against an average of $1.3 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 7620.0% in 2022, then plunged 299.62% in 2023.
- Cellectis' Share-based Compensation stood at $387000.0 in 2022, then soared by 1094.06% to $4.6 million in 2023, then tumbled by 80.87% to $884000.0 in 2024, then jumped by 154.52% to $2.2 million in 2025, then fell by 26.09% to $1.7 million in 2026.
- Business Quant data shows CLLS's Share-based Compensation at $1.7 million in Q1 2026, $2.2 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.66 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 1.28 Mn |
| Mar 31, 2025 | 976,000.00 |
| Mar 31, 2025 | 976,000.00 |
| Dec 31, 2024 | 884,000.00 |
| Dec 31, 2024 | 884,000.00 |
| Sep 30, 2024 | 566,000.00 |
| Sep 30, 2024 | 566,000.00 |
| Jun 30, 2024 | 830,000.00 |
| Jun 30, 2024 | 830,000.00 |
| Mar 31, 2024 | 887,000.00 |
| Mar 31, 2024 | 887,000.00 |
| Dec 31, 2023 | 4.62 Mn |
| Dec 31, 2023 | 4.62 Mn |